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Abstract: Novel advanced spray-dried and co-spray-dried inhalable lung surfactant-mimic 
phospholipid and poly(ethylene glycol) (PEG)ylated lipopolymers as microparticulate/
nanoparticulate dry powders of biodegradable biocompatible lipopolymers were rationally 
formulated via an organic solution advanced spray-drying process in closed mode using 
various phospholipid formulations and rationally chosen spray-drying pump rates. Ratios of 
dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine PEG (DPPE-
PEG) with varying PEG lengths were mixed in a dilute methanol solution. Scanning electron 
microscopy images showed the smooth, spherical particle morphology of the inhalable particles. 
The size of the particles was statistically analyzed using the scanning electron micrographs and 
SigmaScan® software and were determined to be 600 nm to 1.2 µm in diameter, which is optimal 
for deep-lung alveolar penetration. Differential scanning calorimetry (DSC) and powder X-ray 
diffraction (PXRD) were performed to analyze solid-state transitions and long-range molecular 
order, respectively, and allowed for the confirmation of the presence of phospholipid bilayers 
in the solid state of the particles. The residual water content of the particles was very low, as 
quantified analytically via Karl Fischer titration. The composition of the particles was confirmed 
using attenuated total-reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy and con-
focal Raman microscopy (CRM), and chemical imaging confirmed the chemical homogeneity 
of the particles. The dry powder aerosol dispersion properties were evaluated using the Next 
Generation Impactor™ (NGI™) coupled with the HandiHaler® dry powder inhaler device, where 
the mass median aerodynamic diameter from 2.6 to 4.3 µm with excellent aerosol dispersion 
performance, as exemplified by high values of emitted dose, fine particle fraction, and respirable 
fraction. Overall, it was determined that the pump rates defined in the spray-drying process had 
a significant effect on the solid-state particle properties and that a higher pump rate produced 
the most optimal system. Advanced dry powder inhalers of inhalable lipopolymers for targeted 
dry powder inhalation delivery were successfully achieved.
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DPPC (a diacyl 16-saturated carbon chain phospholipid) has 
a transition temperature of 41°C (above physiological body 
temperature of 37°C) when fully hydrated, which may offer 
controlled drug release.1,14,28
The use of poly(ethylene glycol) (PEG)-based liposomal 
formulations has been motivated by the advantage of hav-
ing biocompatible self-assembled drug-delivery systems 
that can evade the recognition and uptake by cells in the 
immune system while prolonging the residence time of the 
liposomes and providing sustained drug release.14,29–32 In addi-
tion, PEG has been recently demonstrated to have inherent 
mucus-penetrating properties.33 Unlike other types of inhaled 
particles, the fate of phospholipid-based particles can have 
a similar fate to native lipids. The processing, uptake, and 
recycling of phospholipid particles occurs through the same 
mechanism as endogenous surfactant via alveolar type II 
pneumocytes.29 In addition, there are successful nanophar-
maceutical products containing PEGylated phospholipid 
for intravenous administration, as it is an FDA-approved 
excipient.14,20,21,32 Sterically stabilized nanomicelles com-
prised of PEGylated phospholipids with encapsulated drug 
for the treatment of acute lung injury by the intravenous route 
have been reported.34,35
The spray-drying method is an advanced high-throughput 
pharmaceutical manufacturing process that is used to effi-
ciently produce and tailor respirable particles in the solid 
state.2,8,14,36 Spray-drying has been used in the microencapsu-
lation of bioactive molecules, as well as in the preparation of 
drug-delivery systems composed of a large variety of biode-
gradable polymers and excipients.37–39 It has also been used 
as a scalable method in the bulk preparation of drug–lipid 
mixtures.37,40,41 The unique features and tunable parameters 
of spray-drying allow for the precise tuning of the particle 
properties as a result of rational design and engineering. The 
use of an organic solvent allows for much lower moisture 
content and smaller particle size (down to 400 nm). This 
along with the inherently lower surface tension of the solvent 
combined with dilute solution concentrations allows particle 
formulation in the solid state in the inhalable range.
The rational design and development of inhalable lung 
surfactant-mimic DPPC and PEGylated phospholipid with 
varying PEG chain length as respirable microparticles 
and nanoparticles as one-component spray-dried (SD) 
and two-component co-SD DPIs for targeted pulmonary 
Introduction
The lung is an ideal target for targeted drug delivery, due to 
the potential to deliver therapeutic aerosols, which allows 
for uniform drug distribution, the avoidance of first-pass 
metabolism, a rapid onset of action, and high drug concentra-
tions within the lung.1–4 Furthermore, the presence of drug 
at the site of pathology with minimal systemic absorption 
leads to decreased side effects.5 Inhalation aerosols enable 
therapeutic effects to be achieved at much lower drug doses 
compared to other routes of administration offering inherently 
longer residence time in the lungs, which can reduce dos-
ing frequency and increase patient compliance.2,5–8  Aerosol 
formulations have been investigated for many pulmonary 
diseases including cystic fibrosis, asthma, chronic obstructive 
pulmonary disease, lung infections, and lung cancer.9–15 Inha-
lation aerosols for the treatment of pulmonary diseases date 
back to ancient times7,16 and many inhalation products exist, 
of which dry powder inhalers (DPIs) are the fastest-growing 
segment. DPI formulations offer many advantages, including 
storing the drug in a dry state, leading to long-term stability,17 
the ability to encapsulate various types of therapeutics,18 and 
the ease of DPI implementation.6,19
Dry powder aerosol formulations of nanoparticles and 
microparticles are of significant interest for direct lung 
delivery.14,20,21 In particular, the use of phospholipids as mul-
tifunctional biocompatible biodegradable excipients for the 
delivery of therapeutics to the lungs is an attractive option.22 
Phospholipids have been shown to improve particle migra-
tion to the lung periphery, owing to the reduction in surface 
tension provided by these biosurfactants,23–27 especially to 
poorly water-soluble drugs. The use of phospholipids in 
 pulmonary delivery is logical in that lung surfactant is a 
mixture  primarily comprised of phospholipids and smaller 
amounts of lung surfactant-specific surface-active proteins.
In particular, dipalmitoylphosphatidylcholine (DPPC) is the 
primary phospholipid component in lung surfactant,  making 
up 55%–60% of the mixture. DPPC serves a vital role in 
reducing the work of breathing, and pulmonary immunity 
modulation, and is used in several successful lung surfactant 
replacement nanopharmaceutical products.14 In addition to 
DPPC being an innate component of the lung, it offers advan-
tages in drug delivery owing to its transition  temperature. 
Transition temperatures of phospholipids are highly 
 dependent on the saturation and length of carbon chains and 
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nanomedicine are reported for the first time in this com-
prehensive and systematic study. The novel aspects of this 
study include organic solution advanced spray-drying in 
closed mode, the rational design and formulation of lung 
surfactant-mimic DPPC together with dipalmitoylphos-
phatidylethanolamine (DPPE)-PEG of varying PEG chain 
lengths as respirable dry powder particles, optimization 
for targeted pulmonary nanomedicine delivery as inhal-
able microparticles and nanoparticles in the solid state, and 
systematic comprehensive analyses. The rational design 
and optimization of these advanced dry powder inhalation 
aerosol nanomedicine formulations as aerosolized lung 
 surfactant-mimic and lipopolymers as DPIs is important 
to allow for better understanding of the physicochemical 
properties and interactions of these particles formulated by 
advanced organic spray-drying and co-spray-drying pro-
cesses in closed mode. To the authors’ knowledge, this is the 
first report on a comprehensive and systematic study on the 
advanced formulation and characteristics of various combina-
tions of DPPC and PEGylated phospholipids comprised of 
various PEG lengths for targeted pulmonary nanomedicine 
as inhaled dry powder aerosols.
Materials and methods
Materials
Synthetic DPPC (molecular weight 734.039 g/mol, .99% 
purity) and DPPE-PEG (molecular weights: 2749.391 g/mol, 
3716.304 g/mol, and 5741.510 g/mol, which correspond 
to 2000, 3000, and 5000 molecular weight PEG lengths 
per compound; .99% purity) were obtained from Avanti 
Polar Lipids (Alabaster, AL). Their corresponding  chemical 
structures are shown in Figure 1 (ChemSketch 12.01; 
Advanced Chemistry Development, Toronto, Canada). 
Methanol (high-performance liquid chromatography [HPLC] 
grade, American Chemical Society [ACS]-certified and 
chloroform [HPLC grade, ACS certified]) was obtained 
from Fisher Scientific (Pittsburgh, PA). Hydranal-Coulomat 
AD was from Sigma-Aldrich (St Louis, MO). Ultrahigh-
purity (UHP) dry nitrogen gas was from Scott-Gross 
(Lexington, KY). All materials were used as stored in the 
freezer at −23°C and used as received.
Organic solution advanced spray-drying 
and co-spray-drying in closed mode  
from dilute solution
Advanced spray-drying of single-component DPPC 
and PEGylated phospholipids and co-spray drying of 
DPPC:PEGylated two-component systems from dilute 
organic solution was performed with a B-290 Büchi Mini 
Spray Dryer coupled with a B-295 Inert Loop and high-
performance cyclone (all from Büchi Labortechnik, Flawil, 
Switzerland) in closed mode using UHP dry nitrogen gas 
as the atomizing gas. The feed solutions were prepared by 
dissolving various amounts of DPPC and/or DPPE-PEG in 
methanol to form dilute organic solutions of 0.1% w/v. Based 
on our previous organic solution advanced spray-drying 
work,42 the following spray-drying conditions were used: 
atomization gas flow rate of 600 L/hour, aspiration rate of 
35 m3/hour, inlet temperature of 150°C (maintained in the first 
spray-drying process), and three different pump rates, desig-
nated as “low P,” “med P,” and “high P” pump rates, which 
corresponded to 3 mL/minute (10%), 15 mL/minute (50%), 
and 30 mL/minute (100%), respectively. Table 1 shows the 
various formulated particle systems and their corresponding 
DPPC and DPPE-PEG amounts and types, pump rates, and 
outlet temperatures (which represent the secondary drying 
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Figure 1 Chemical structures of (A) dipalmitoylphosphatidylcholine and (B) dipalmitoylphosphatidylethanolamine methoxy-poly(ethylene glycol).
Notes: n = 45, 67, and 113 for 2000, 3000, and 5000 MW poly(ethylene glycol), respectively, where n denotes the number of ethylene glycol oligomers present.
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process temperatures). The nozzle diameter (composed of 
stainless steel) was 0.7 mm, and the spray-dried particles 
were separated from the drying gas (UHP nitrogen) in 
the high-performance cyclone and collected in a sample 
 collector. All SD and co-SD powders were stored in glass 
vials sealed with parafilm in glass desiccators over Drierite 
(Xenia, OH) desiccant in the freezer at −23°C under ambi-
ent pressure.
Scanning electron microscopy  
for morphology and shape analysis
The shape and surface morphology of particles was 
evaluated by scanning electron microscopy (SEM), using 
a Hitachi S-4300 microscope (Tokyo, Japan). Samples 
were placed on double-sided adhesive carbon tabs and 
were adhered to aluminum stubs (TedPella, Redding, CA) 
which were coated with a gold/palladium alloy thin film 
using an Emscope SC400 sputter coating system at 20 µA 
for 1 minute under argon gas. The electron beam with an 
accelerating voltage of 5–10 kV was used at a working 
distance of 13.3–15.3 mm. Images were captured at several 
magnifications.
Particle sizing and size  
distribution using SEM
The mean size, standard deviation, and size range of the parti-
cles were determined digitally using SigmaScan® 5.0 software 
(Systat, San Jose, CA). Representative micrographs for each 
particle sample at 5000× magnification were analyzed by 
measuring the diameter of at least 100 particles per image 
with the SigmaScan software.
Powder X-ray diffraction
Using similar conditions previously reported by the authors,42 
powder X-ray diffraction (PXRD) patterns of powder samples 
were measured by a Rigaku Multiflex X-ray diffractometer 
(The Woodlands, TX) with a slit-detector Cu Kα radiation 
source (40 kV, 44 mA, and λ = 1.5406 Å). The scan range 
was 5.0–50.0 2θ (°) with a scan rate of 2.0°/minute at ambient 
temperature. The sample was placed on a horizontal quartz 
glass sample holder plate.
Differential scanning calorimetry
Thermal analysis and phase-transition measurements were 
carried out using a TA Q200 differential scanning calorimetry 
(DSC) system (TA Instruments, New Castle, DE) equipped 
with T-Zero® technology and an automated computer-
 controlled RSC-90 cooling accessory. Using similar condi-
tions previously reported by the authors,42 1–3 mg of powder 
was weighed into hermetic anodized aluminum T-Zero® DSC 
pans and were hermetically sealed with the T-Zero® hermetic 
sealer. UHP dry nitrogen gas was used as the purging gas at 
50 mL/minute. The heating range was 0°C–250°C at a heating 
scan rate of 5.00°C/minute.
Karl Fischer coulometric titration
The water content of all powders was chemically quantified 
by Karl Fisher (KF) coulometric titration, using similar condi-
tions previously reported by the authors.42 The measurements 
were performed with a 737 KF Coulometer coupled with 703 
Ti Stand (Metrohm, Antwerp, Belgium). Approximately 5 mg 
of powder was dissolved in a known volume of  chloroform. 
The sample solution was injected into the  reaction cell that 
Table 1 Formulated spray-dried and co-spray-dried particle systems, their corresponding DPPC and/or DPPE-PEG amounts, and 
spray-drying conditions where low P, medium P, and high P correspond to 10%, 50%, and 100% pump rates, respectively
System DPPC (mol%) DPPE-PEG 
(mol% and PEG MW)
Pump rate  
(mL/minute) (%)
Outlet T 
(°C)
100 DPPC (low P) 100 0 3 (10%) 85
100 DPPC (medium P) 100 0 15 (50%) 70
100 DPPC (high P) 100 0 30 (100%) 49
95 DPPC:5 DPPE-PEG2k (low P) 95 5 (2k) 3 (10%) 71
95 DPPC:5 DPPE-PEG2k (medium P) 95 5 (2k) 15 (50%) 73
95 DPPC:5 DPPE-PEG2k (high P) 95 5 (2k) 30 (100%) 40
95 DPPC:5 DPPE-PEG3k (low P) 95 5 (3k) 3 (10%) 73
95 DPPC:5 DPPE-PEG3k (medium P) 95 5 (3k) 15 (50%) 79
95 DPPC:5 DPPE-PEG3k (high P) 95 5 (3k) 30 (100%) 43
95 DPPC:5 DPPE-PEG5k (low P) 95 5 (5k) 3 (10%) 69
95 DPPC:5 DPPE-PEG5k (medium P) 95 5 (5k) 15 (50%) 64
95 DPPC:5 DPPE-PEG5k (high P) 95 5 (5k) 30 (100%) 37
Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; PEG, poly(ethylene glycol).
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contained Hydranal KF reagent and the water content was 
then calculated from the resulting reading.
Attenuated total-reflectance fourier-
transform infrared spectroscopy
Attenuated total-reflectance Fourier-transform infrared 
spectroscopy (ATR-FTIR) was performed using a Varian 
7000e step-scan spectrometer (Agilent Technologies, Santa 
Clara, CA). The powder was placed on the diamond ATR 
crystal, covered with a glass coverslip, and held in place 
with a specialized clamp. ATR crystal and IR spectra were 
obtained at an 8 cm−1 spectral resolution between 700 and 
4000 cm−1. The data were collected and analyzed using Varian 
Resolutions software.
Hot-stage microscopy under  
cross-polarizers
Using similar conditions previously reported by the authors,42 
hot-stage microscopy (HSM) studies were completed using 
a BX51 polarized microscope (Olympus, Tokyo, Japan) 
equipped with an Instec STC200 heating unit and S302 hot 
stage (Boulder, CO). The polarized light was filtered by a γ 
530 nm U-TP530 filter lens. Powder samples were mounted 
on a cover glass and heated from 25°C to 250°C at a heating 
scan rate of 5°C/minute. The heating program was controlled 
by WinTemp software, and images were digitally captured 
via a SPOT Insight digital camera (Diagnostic Instruments, 
Sterling Heights, MI).
Confocal Raman microscopy  
and spectroscopy
Confocal Raman microspectroscopy (CRM) was performed 
using an Aramis confocal dispersive Raman spectrometer 
and fluorescence microscope system (Horiba Jobin Yvon, 
Edison, NJ), using similar conditions previously reported by 
the authors.43 The system is equipped with an Olympus BX41 
confocal optical microscope and an Olympus U-LH 100 W 
Hg lamp and U-RFL-T power source used for fluorescence 
excitation and bright-field illumination. All optical images 
and Raman spectra were obtained using a 50× objective. 
Raman spectra and spectral maps were acquired using a 
633 nm HeNe laser. Spectral maps were obtained with the 
stage moved in increments of 2 µm. Each map point was 
acquired using 2 seconds of detector exposure time, with 
32 accumulations acquired per point using a grating of 
600 grooves/mm and a center wavenumber of 1200 cm−1 
(for spectra in the fingerprint region) and two accumulations 
acquired per point, with a grating of 950 grooves/mm and 
a center wavenumber of 2900 cm−1 (for the C–H stretching 
region). A confocal hole of 500 µm and a slit width of 100 µm 
were used. Spectra covering the range of 200–4000 cm−1 
were obtained in automatic scanning mode using the 
950 groove/mm grating. Spectra were subjected to baseline 
correction and smoothing prior to further analysis.
Aerosol dispersion performance analysis 
by Next Generation Impactor™ (NGI™)
In accordance with the United States Pharmacopeia chap-
ter 601 specifications on aerosols,44 the aerosol-dispersion 
properties of the dry powder particles as DPIs were deter-
mined using the Next Generation Impactor™ (NGI™) with 
a stainless steel induction port (ie, United States Pharmaco-
peia throat) attachment (model 170; MSP, Shoreview, MN), 
equipped with specialized stainless steel NGI™ gravimetric 
insert cups (MSP). The NGI™ was coupled with a Copley 
TPK 2000 critical flow controller (Copley Scientif ic, 
 Nottingham, UK), which was connected to an HCP5 vacuum 
pump (Copley Scientific). The airflow rate, Q, was measured 
and adjusted prior to each experiment using a DFM 2000 
flow meter (Copley Scientific).
The aerosolization studies were experimentally designed 
by Design Expert® 8.0.7.1 software (Stat-Ease, Minneapolis, 
MN). Glass-fiber filters (55 mm, type A/E; Pall Life Sciences, 
Exton, PA) were placed in the stainless steel NGI™ gravi-
metric insert cups for NGI™ stages 1–7 to minimize bounce 
or reentrapment.45 Three hydroxypropyl methylcellulose hard 
capsules (size 3, Quali-V®; Qualicaps, Whitsett, NC) were 
each loaded with 10 mg of powder and were then loaded into 
a high-resistance (ie, high sheer stress) human DPI device, 
the HandiHaler® (Boehringer Ingelheim, Ridgefield, CT), and 
tightly inserted into the induction port. The NGI™ was run at 
a controlled flow rate at Q = 60 L/minute with a delay time 
of 10 seconds (NGI™ Flow controller) prior to the capsules 
being needle-pierced open by the HandiHaler® mechanism, 
where the particles were then drawn into the inertial impactor 
for 10 seconds. This was done with a total of three capsules 
per sample for a total of 30 mg total per run. For each 30 mg 
run, the amount of particles deposited onto each stage was 
determined gravimetrically by measuring the difference in 
mass of the glass filters after particle deposition. For the 
NGI™ Q = 60 L/minute, the effective cutoff diameters for 
each impaction stage were calibrated by the manufacturer 
and stated as: Stage 1 (8.06 µm); Stage 2 (4.46 µm); Stage 3 
(2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 
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(0.55 µm); and Stage 7 (0.34 µm). The fine particle dose 
(FPD), fine particle fraction (FPF), respirable fraction (RF), 
and emitted dose (ED) were calculated as follows:
 FPD = mass of particles , 4.4 µm (stages 2–7)
 
FPF
Fine particle dose
Initial particle mass loaded into ca
=
psules 
×100%
 
RF
Mass of particles < 4.4 m (  2  7)
Total par
= µ stages through
ticle mass on all stages
× 100%
ED = [(initial mass in capsules - final mass remaining in capsules)
/initial mass in capsules]   100%×



The mass mean aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) were determined using 
a mathematical program written by Dr Warren Finlay. All 
experiments were triplicated (n = 3).
Results
SEM, particle sizing, and size distribution
Formulated particle and surface morphologies were visu-
alized and analyzed via SEM. Figures 2–5 include SEM 
A
WD 15.0 mm 10.0 kV x1.0 k 50 µm WD 14.8 mm 5.0 kV x10k 5 µm
WD 15.3 mm 10.0 kV x10 k 5 µm WD 14.9 mm 5.0 kV x10 k 5 µm
B
C D
Figure 2 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylcholine (DPPC) and spray-dried 100 DPPC particles at three pump rates. (A) Raw DPPC, 
magnification 1000×; (B) DPPC particles at 10% (low P) pump rate, magnification 10,000×; (C) DPPC particles at 50% (medium P) pump rate, magnification 10,000×; 
(D) DPPC particles at 100% (high P) pump rate, magnification 10,000×.
micrographs of the particles at 10,000× and corresponding 
raw DPPC or DPPE-PEG at 1000×. Their corresponding 
size (diameter), standard deviation, and range are exhibited 
in Table 2, as determined using SigmaScan® software. 100 
DPPC (pure one-component DPPC)-formulated particles 
are smooth and spherical, and their diameter increased 
with increasing pump rate (diameters of 0.642 ±0.188, 
0.790 ± 0.292, and 0.960 ± 0.499 µm for low P, medium P, 
and high P,  respectively). Formulated 95 DPPC:5 DPPE-
PEG2k particle size also increased with increasing pump 
rate; however, only the high P formulation exhibited spheri-
cal morphology and a diameter of 1.166 ± 0.676 µm. Low P 
and high P particle systems were rough and agglomerated, 
and their diameter could not be determined. Similarly, 95 
DPPC:5 DPPE-PEG3k and 95 DPPC:5 DPPE-PEG5k for-
mulated particle sizes increased with increasing pump rate, 
and the high P formulations were spherical with diameters 
of 1.200 ± 0.931 µm and 1.161 ± 0.595 µm, respectively. 
The low P and medium P formulations for both systems 
were agglomerated and rough, and their diameters were not 
determined. Also, the surface roughness of the high P particle 
formulations seemed to be rough. This was a result of charg-
ing of the particles during SEM, as their initial morphology 
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A B
C D
WD 15.1 mm 10.0 kv x1.2 k 25 µm WD 13.3 mm 5.0 kv x10 k 5 µm
WD 15.3 mm 10.0 kv x10 k 5 µm WD 13.4 mm 5.0 kv x10 k 5 µm
Figure 3 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k 95 DPPC:5 DPPE-PEG2k and co-spray-dried 95 
dipalmitoylphosphatidylcholine (DPPC):5 DPPE-PEG 2k particles at three pump rates. (A) Raw DPPE-PEG2k, magnification 1000×; (B) 95 DPPC:5 DPPE-PEG2k particles at 
10% (low P) pump rate, magnification 10,000×; (C) 95 DPPC:5 DPPE-PEG2k particles at 50% (medium P) pump rate, magnification 10,000×; (D) 95 DPPC:5 DPPE-PEG2k 
particles at 100% (high P) pump rate, magnification 10,000×.
A B
C D
WD 15.1 mm 10.0 kv x1.2 k WD 15.2 mm 10.0 kv x10 k 5 µm
WD 15.3 mm 10.0 kv x10 k 5 µmWD 15.1 mm 10.0 kv x10 k 5 µm
25 µm
Figure 4 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k (DPPE-PEG3k) and co-spray-dried 95 
dipalmitoylphosphatidylcholine (DPPC):5 DPPE-PEG3k particles at three pump rates. (A) Raw DPPE-PEG3k, magnification 1000×; (B) 95 DPPC:5 DPPE-PEG3k particles at 
10% (low P) pump rate, magnification 10,000×; (C) 95 DPPC:5 DPPE-PEG3k particles at 50% (medium P) pump rate, magnification 10,000×; (D) 95 DPPC:5 DPPE-PEG3k 
particles at 100% (high P) pump rate, magnification 10,000×.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
281
Dry powder DPPC: DPPE-PEG aerosols
International Journal of Nanomedicine 2013:8
A B
C D
WD 14.8 mm 10.0 kv x1.5 k 20 µm WD 14.8 mm 10.0 kv x10 k 5 µm
WD 14.9 mm 5.0 kv x10 k 5 µm WD 13.3 mm  5.0 kv x10 k 5 µm
Figure 5 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-5k (DPPE-PEG5k) and co-spray-dried 95 
dipalmitoylphosphatidylcholine (DPPC):5 DPPE-PEG 5k particles at three pump rates. (A) Raw DPPE-PEG5k, magnification 1000×; (B) 95 DPPC:5 DPPE-PEG 5k particles at 
10% (low P) pump rate, magnification 10,000×; (C) 95 DPPC:5 DPPE-PEG 5k particles at 50% (medium P) pump rate, magnification 10,000×; (D) 95 DPPC:5 DPPE-PEG 5k 
particles at 100% (high P) pump rate, magnification 10,000×.
Table 2 Particle-size parameters of spray-dried DPPC and 
co-spray-dried DPPC:DPPE-PEG particles (mean ± standard 
deviation)
System Diameter (μm) Range (μm)
100 DPPC (low P) 0.642 ± 0.188 0.274–1.157
100 DPPC (medium P) 0.790 ± 0.292 0.228–1.755
100 DPPC (high P) 0.960 ± 0.499 0.220–2.000
95 DPPC:5 DPPE-PEG2k (high P) 1.166 ± 0.676 0.360–4.068
95 DPPC:5 DPPE-PEG3k (medium P) 1.049 ± 0.529 0.303–3.775
95 DPPC:5 DPPE-PEG3k (high P) 1.200 ± 0.931 0.034–5.298
95 DPPC:5 DPPE-PEG5k (medium P) 0.837 ± 0.299 0.316–1.759
95 DPPC:5 DPPE-PEG5k (high P) 1.161 ± 0.595 0.326–2.966
Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphati-
dylethanolamine; PEG, poly(ethylene glycol).
prior to image capture was smooth and spherical. Overall, the 
particle sizes exhibited by all formulated microparticulate/
nanoparticulate powders were in the respirable size range.
Powder X-ray diffraction
Powder X-ray diffractograms (Figure 6) showed the pres-
ence of a strong peak at 21° 2Θ for both raw DPPC and all 
formulated 100 DPPC particles, which corresponds to the 
presence of the lipid bilayer.37 Raw DPPE-PEG showed the 
presence of strong peaks at 19° and 23° 2Θ, a small peak at 
21° 2Θ, and smaller broad peaks above 25° 2Θ. The peaks 
at 19°, 23°, and above 25° 2Θ are similar to previous results 
for PEG powder,46 whereas the peak at 21° 2Θ corresponds 
to the presence of a phospholipid bilayer. Upon spray-drying, 
the peaks above 25° 2Θ disappeared, whereas the peaks at 
19° and 23° 2Θ remained for all formulated particle systems. 
Furthermore, the peak present at 21° 2Θ increased due to 
the influence of DPPC in the particle formulation. Although 
there was no correlation in peak intensity with spray-drying 
pump rates, the intensity of the peaks corresponding to PEG 
increased with increasing PEG chain length for the raw 
DPPE-PEG compounds.
Differential scanning calorimetry
DSC thermograms for formulated particles and their corre-
sponding raw counterparts can be seen in Figure 7. Raw DPPC 
exhibited three endothermic peaks, including a crystal-to-gel 
(T
c
) bilayer phase transition at ∼47.1°C, pretransition peak 
corresponding to a gel-to-ripple (T
p
) phase at ∼67.0°C, and 
the bilayer main phase transition (T
m
) to the liquid crystal-
line phase at ∼72.0°C, where the hydrophobic acyl chain core 
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Figure 6 Powder X-ray diffractograms of: (A) formulated spray-dried (SD) dipalmitoylphosphatidylcholine (DPPC) particles at three pump rates versus raw DPPC; 
(B) formulated co-SD DPPC: dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) particles at three pump rates versus raw DPPC and raw DPPE-
PEG2k; (C) formulated co-SD DPPC:DPPE-PEG3k particles at three pump rates versus raw DPPC and raw DPPE-PEG3k; (D) formulated co-SD DPPC:DPPE-PEG5k particles 
at three pump rates versus raw DPPC and raw DPPE-PEG5k.
Note: Low P, med P, and high P correspond to 10%, 50%, and 100% pump rates, respectively.
melted. This is consistent with our earlier findings on raw 
DPPC powder.24 The phase behavior of solid-state DPPC, fully 
hydrated DPPC, and at varying levels of water content in the 
solid state have been previously reported by the authors.24–26 
Formulated 100 DPPC particles exhibited the characteristic 
bilayer main transition phase (T
m
) at ∼68°C, which cor-
responds to the bilayer main transition phase of raw DPPC 
confirming the presence of the phospholipid bilayer. The 
bilayer phase temperatures for SD DPPC were slightly lower 
than that of the raw DPPC, and it was determined that the heat 
of fusion of the formulated particles increased with increas-
ing pump rate (24.8, 29.2, and 36.1 J/g for low P, medium P, 
and high P, respectively). Neither T
c
 nor T
p
 were observed in 
the thermograms for the SD DPPC particles, indicating that 
spray-drying rendered the bilayers in the gel state (not the 
crystalline state, as was observed with raw DPPC). All DPPC 
systems underwent decomposition around 160°C.
Raw DPPE-PEG2k exhibited two endothermic peaks, 
including a pretransition peak at 43.5°C and main phase 
transition at ∼52.1°C. The co-SD 95 DPPC:5 DPPE-PEG2k 
particle systems exhibited two endothermic peaks: the 
first around 47°C, which corresponds to the DPPE-PEG 
main phase transition (T
c
), and the second in the range 
of 70°C–75°C, which corresponds to the DPPC bilayer 
main phase transition − T
m
. Furthermore, the low P sample 
exhibited a third endotherm near 90°C. Raw DPPE-PEG3k 
exhibited a single endothermic peak at 52.0°C, corresponding 
to the main phase transition. The 95 DPPC:5 DPPE-PEG3k 
particles exhibited two endothermic peaks near 49.5°C 
(corresponding to the DPPE-PEG3k transition phase) and 
74°C (corresponding to the DPPC bilayer phase transition). 
For the DPPC bilayer phase transition peaks, the heat of 
fusion increased with increasing pump rate at 2.0, 10.7, and 
17.0 J/g for low P, medium P, and high P, respectively. The 
low P particles had a third endotherm near 100°C. Similarly, 
raw DPPE-PEG5k exhibited a pretransition peak at 48.3°C 
and main phase transition at 57.9°C. The 95 DPPC:5 DPPE-
PEG5k particles showed two endothermic peaks at 55.3°C 
and 73°C, which corresponded to the main phase transition 
of DPPE-PEG5k and DPPC, respectively. For the DPPC 
bilayer phase transition peaks, the heat of fusion increased 
with increasing pump rate at 2.6, 11.0, and 14.7 J/g for low P, 
medium P, and high P, respectively. The low P particles had 
a third endotherm near 100°C.
For the main phase transition temperatures corresponding 
to the DPPE-PEG peaks (first endotherms for  formulated 
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Figure 7 Differential scanning calorimetry thermograms of: (A) formulated spray-dried (SD) dipalmitoylphosphatidylcholine (DPPC) particles at three pump rates versus 
raw DPPC; (B) formulated co-SD DPPC:dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) particles at three pump rates versus raw DPPE-PEG2k; 
(C) formulated co-SD DPPC:DPPE-PEG3k particles at three pump rates versus raw DPPE-PEG3k; (D) formulated co-SD DPPC:DPPE-PEG5k particles at three pump rates 
versus raw DPPE-PEG5k.
Note: Low P, med P, and high P correspond to 10%, 50%, and 100% pump rates, respectively. 
co-SD DPPC:DPPE-PEG particles), the temperature 
increased with increasing PEG molecular weight. Also, the 
peaks corresponding to DPPE-PEG in the formulated co-SD 
powders are broader and result in high heats of fusion in 
comparison to the DPPC-related peaks. Furthermore, all 
formulated co-SD 95 DPPC:5 DPPE-PEG and raw DPPE-
PEG samples decomposed above 130°C.
Karl Fischer coulometric titration
The residual water content in the solid state of the formulated 
particles and their raw components are shown in Table 3. 
The water content of raw DPPC was 1.74% ± 0.15% (w/w) 
and ranged from 4.59% to 5.17% (w/w) for SD 100 DPPC 
particles. The water content for raw DPPE-PEG2k was 
0.70% ± 0.21% (w/w) and ranged from 1.29% to 3.13% 
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Table 3 Water content of formulated spray-dried DPPC and co-
spray-dried DPPC:DPPE-PEG particles and their raw counterparts 
analyzed via Karl Fischer coulometric titration (mean ± standard 
deviation, n = 3)
System Water% (w/w)
100 DPPC (low P) 4.93 ± 1.29
100 DPPC (medium P) 4.59 ± 1.03
100 DPPC (high P) 5.17 ± 1.29
Raw DPPC 1.74 ± 0.15
95 DPPC:5 DPPE-PEG2k (low P) 1.29 ± 0.70
95 DPPC:5 DPPE-PEG2k (medium P) 3.13 ± 1.17
95 DPPC:5 DPPE-PEG2k (high P) 1.76 ± 0.83
Raw DPPE-PEG2k 0.70 ± 0.21
95 DPPC:5 DPPE-PEG3k (low P) 2.43 ± 0.60
95 DPPC:5 DPPE-PEG3k (medium P) 2.82 ± 0.89
95 DPPC:5 DPPE-PEG3k (high P) 4.34 ± 1.71
Raw DPPE-PEG3k 0.60 ± 0.12
95 DPPC:5 DPPE-PEG5k (low P) 1.46 ± 0.75
95 DPPC:5 DPPE-PEG5k (medium P) 1.65 ± 0.26
95 DPPC:5 DPPE-PEG5k (high P) 3.11 ± 1.11
Raw DPPE-PEG5k 1.04 ± 0.65
Note: Low P, medium P, and high P correspond to 10%, 50%, and 100% pump rates, 
respectively. 
Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphos-
phatidylethanolamine; PEG, poly(ethylene glycol).
(w/w) for formulated co-SD 95 DPPC:5 DPPE-PEG2k 
particles. For raw DPPE-PEG3k, the water content was 
0.60% ± 0.12% (w/w) and for formulated co-SD 95 DPPC:5 
DPPE-PEG3k, particles ranged from 2.82% to 4.34% 
(w/w). Finally, the water content for raw DPPE-PEG5k was 
1.01% ± 0.65% (w/w), whereas it ranged from 1.46% to 
3.11% (w/w) for the formulated co-SD 95 DPPC:5 DPPE-
PEG5k particles. There was no trend in the water-content 
values for formulated systems based on the spray-drying 
pump rates or type of DPPE-PEG used. All water-content 
values were low and well within an acceptable range for 
inhalable dry powder formulations.
Cross-polarizing light hot-stage microscopy
Representative micrographs of raw DPPE-PEG3k and 
formu lated co-SD 95 DPPC:5 DPPE-PEG3k (high P) 
particles are shown in Figures 8 and 9, respectively. Raw 
DPPE-PEG3k showed dark agglomerates lacking birefrin-
gency between 25°C and 55°C, which indicated a noncrystal-
line, amorphous material. A phase transition was visualized 
by HSM near 57°C to 58°C, which likely corresponded to 
the gel to liquid-crystal transition, as shown in the DSC ther-
mogam at 52°C for raw DPPE-PEG3k in Figure 7C. Melting 
was visualized starting at 60°C by the formation of liquid 
droplets, with decomposition occuring above 150°C.
The micrographs for co-SD 95 DPPC:5 DPPE-PEG3k 
(high P) particles also showed dark agglomerates lacking 
birefringency between 25°C and 100°C, which indicated 
a noncrystalline, amorphous material. No visible phase 
transition was evident and melting started around 115°C, 
as shown by liquid droplet formation. Decomposition was 
evident above 185°C. This behavior corresponds closely to 
that observed for raw DPPC (data not shown), which is the 
primary component of these particles.
Attenuated total-reflectance fourier-
transform infrared spectroscopy
Formulated particles and their raw counterparts underwent 
ATR-FTIR analysis to determine the functional groups pres-
ent in the systems, as shown in Figure 10. For both the raw 
DPPC and SD 100 DPPC particles, the spectra indicated 
the same characteristic peaks for all systems and were the 
same as in previously reported literature.47 The spectra for 
formulated co-SD 95 DPPC:5 DPPE-PEG particles, however, 
exhibited peaks corresponding to DPPC and/or DPPE-PEG. 
 Interestingly, the characteristic peaks shown for raw DPPE-
PEG were the same as previously shown for pure PEG,48 
showing the strong influence of the PEG presence in the 
analysis of these systems. Although there is the absence of a 
broad water peak (3200–3400 cm−1) for the raw DPPE-PEGs, 
this peak was present in both the raw DPPC and SD 100 
DPPC particles as well as the formulated co-SD 95 DPPC:5 
DPPE-PEG particles. While certain peaks relating to charac-
teristic functional groups relate to DPPC or DPPE-PEG only, 
some are shared by both and have an influence on the formu-
lated co-SD DPPC:DPPE-PEG particles. For instance, peaks 
present in the formulated DPPC:DPPE-PEG particles that 
are due to the influence of DPPC include those at 2924 cm−1 
(–CH
2
 antisymmetrical stretching), 2852 cm−1 (–CH
2
 sym-
metrical stretching), 1250–1350 cm−1 (P=O stretching), and 
721 cm−1 (–N+[CH
3
]
3
 symmetrical stretching). Peaks due to 
the influence of DPPE-PEG (PEG) include 2870 cm−1 (–CH
3
 
symmetrical stretching), 1342 cm−1 (alcohols), and 1276 cm−1 
(ethers). Peaks in the formulated particles due to the influ-
ence of DPPC and/or DPPE-PEG (present in all three) 
include 1720–1735 cm−1 (C–O ester stretching), 1465 cm−1 
(–CH
2
 deformation, 1050–1150 cm−1 (–C–C–) and 960 cm−1 
(–N+[CH
3
]
3
) antisymmetrical stretching).
Confocal Raman microscopy  
and chemical imaging
Confocal Raman microscopy (CRM) and chemical imaging 
was performed first on raw DPPC for comparison with formu-
lated SD DPPC particles. The results are shown in Figure 11. 
The full-range Raman spectra obtained via the microscope 
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Figure 9 Representative hot-stage micrographs for co-spray-dried 95 dipalmitoylphosphatidylcholine:5 dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k 
(high P) particles. 
Note: Scale bar = 3 mm.
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Figure 8 Representative hot-stage micrographs for raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k.
Note: Scale bar = 3 mm.
at several different points showed no difference between the 
raw and SD DPPC, as seen in the selected spectra shown in 
Figure 11A. Two 32 × 32 maps were made at regions of the 
Raman spectrum centered at 2900 and 1200 cm−1. A repre-
sentative map of the region between 1400 and 1520 cm−1 is 
shown in Figure 11B and illustrates the observed results. The 
intensity variation observed in the red map was minor and 
showed no evidence of inhomogeneity within the particle. 
The variation is likely caused by sample height effects and 
minor density variations within the particle.
Raman microscopy and chemical imaging was also used 
to assess the homogeneity of formulated co-SD 95 DPPC:5 
DPPE-PEG2k (high P) particles. Bands were identified that 
were specific for DPPC and DPPE-PEG2k, as shown in 
Figure 12A. Two regions were selected that were specific 
for DPPE-PEG2k, between 270 and 295 cm−1 and between 
1225 and 1250 cm−1. For DPPC, a band at 700 and 740 cm−1 
was chosen. The areas of these bands were extracted from a 
32 × 32 Raman spectral map, and are shown in  Figure 12B–D. 
The blue, green, and red maps align with the bands denoted 
by colored arrowheads in Figure 12A. The map intensity 
observed for the selected bands, which are specific to the 
two chemical components of the particle, is seen to correlate 
between the three maps, indicating that DPPC and DPPE-
PEG2k are similarly distributed in the particle at the resolu-
tion limit of Raman microscopy. Variations in the band area 
are caused by sample height effects and density variations 
within the mapped particle. Formulated co-SD 95 DPPC:5 
DPPE-PEG3k (high P) particles were examined in a similar 
manner using the same set of Raman bands, leading to the 
results shown in Figure 13. Again, the colored maps correlate 
with each other and indicate that DPPC and DPPE-PEG3k 
are distributed similarly. Formulated 95 DPPC:5 DPPE-
PEG5k (high P) particles were also examined using the 
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Figure 10 Attenuated total-reflectance Fourier-transform infrared spectra of: (A) formulated spray-dried (SD) dipalmitoylphosphatidylcholine (DPPC) particles at three 
pump rates versus raw DPPC; (B) formulated co-SD DPPC:dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) particles at three pump rates versus 
raw DPPC and raw DPPE-PEG2k; (C) formulated co-SD DPPC:DPPE-PEG3k particles at three pump rates versus raw DPPC and raw DPPE-PEG3k; (D) formulated co-SD 
DPPC:DPPE-PEG5k particles at three pump rates versus raw DPPC and raw DPPE-PEG5k.
Note: Low P, med P, and high P correspond to 10%, 50%, and 100% pump rates, respectively.
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Figure 11 (A) Raman spectra obtained via confocal microscopy of raw 
dipalmitoylphosphatidylcholine (DPPC) and formulated spray-dried (SD) DPPC at 
100% pump rate. The colored arrowhead shows the mapped bands. (B) Raman 
spectroscopic mapping showing the area of the Raman bands between 1400 and 
1520 cm−1 (brighter-red colors indicate greater area) superimposed on a bright-field 
optical image of the surface of a particle of formulated SD DPPC (100% pump rate).
same approach, as shown in Figure 14, and also indicated a 
homogenous distribution of DPPC and DPPE-PEG5k.
Aerosol dispersion performance analysis 
using the Next Generation Impactor™ 
(NGI™)
The aerosol properties of the formulated particles produced at 
the highest pump rate (high P) were evaluated using an NGI 
coupled with the HandiHaler® DPI device (FDA-approved). 
The MMAD and geometric standard deviation values were 
similar for all four systems that were analyzed, ranging between 
4.0 and 4.5 µm and 2.1 and 2.7 µm, respectively. The fine-
particle dose increased upon using PEGylated phospholipids 
where SD 100 DPPC was 23.8% and co-SD 95 DPPC:5 DPPE-
PEG2k, 3k, and 5k were 29.4%, 30.2%, and 29.5%, respectively. 
The ED was similar for all four systems, ranging from 91.2% 
to 94.2%, whereas the RF% increased with increasing 
PEGylation of the particles. These RF% values were 60.3% for 
SD 100 DPPC and co-SD 95 DPPC:5 DPPE-PEG2k, 3k, and 
5k were at 68.7%, 71.7% and 75.5%, respectively. Figure 15 
demonstrates the actual aerosol dispersion performance of 
the engineered dry powder microparticulate/nanoparticulate 
aerosols showing the % deposition on each NGI™ stage. 
Aerosol deposition on each NGI™ stage is measured, and in 
particular deposition on the lower stages of stage 2 all the way 
to stage 7 (lowest stage) is observed.
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Figure 12 (A) Raman spectra obtained via confocal microscopy of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k), formulated spray-dried 
(SD) dipalmitoylphosphatidylcholine (DPPC), and formulated co-SD 95 DPPC:5 DPPE-PEG2k (high P). Colored arrowheads show mapped bands. (B) Raman spectroscopic 
mapping showing the area of the Raman bands between 700 and 740 cm−1 (brighter colors indicate greater area) superimposed on a bright-field optical image of the surface 
of a particle of formulated SD DPPC (100% pump rate). (C) Map showing the area of the Raman bands between 270 and 295 cm−1. (D) Map showing the area of the Raman 
bands between 1225 and 1250 cm−1.
Discussion
This comprehensive and systematic study illustrates the 
physicochemical properties of DPPC and DPPC:DPPE-PEG 
microparticles and nanoparticles rationally designed for 
the first time by an organic solution closed-mode advanced 
spray-drying. Furthermore, this study also demonstrates for 
the first time their aerosol dispersion performance as DPIs 
for targeted pulmonary nanomedicine delivery, with excel-
lent properties for high aerosol dispersion performance as 
dry powder inhalation aerosols. A systematic experimental 
design resulted in the successful design, development, and 
optimization of twelve particle systems, which included pure 
one-component SD DPPC particles and two-component 
co-SD 95 mole% DPPC:5 mole% DPPE-PEG DPI particles 
(using three different PEG chain lengths) at three different 
pump rates. This study strived to elucidate the effects of the 
presence of DPPE-PEG, PEG chain length, and the effects 
of the pump rate.
Overall, the use of dilute organic solution (such as 
alcohols, which are considered “green” chemicals) imparts 
a smaller primary droplet size by virtue of lower surface 
tension in the range of 20–25 mN/m (in contrast to water, 
which has a high surface tension of 72 mN/m and hence 
produces larger primary droplets) with rationally designed 
advanced spray-drying conditions resulted in the optimization 
of particle characteristics necessary for effective dry powder 
delivery. In addition, organic solution advanced spray-drying 
in closed mode eliminates the need for water and minimizes 
the residual water content in the final powder. This is an 
important and novel aspect reported here, as minimizing 
the residual water content in the solid state improves aerosol 
dispersion performance and promotes solid-state stability. 
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SEM  analysis showed that the particles exhibited an ideal size 
range (0.5–1.5 µm), which is comparable to respirable treha-
lose dry powder particles in the 0.75–0.99 µm range made by 
the novel process of organic solution advanced spray-drying 
in closed-mode, as earlier reported by these authors.49 The 
size and morphology of particles utilized in the inhalation 
application is paramount in ensuring targeted delivery to 
specific lung regions, since particles in the stated size range 
are capable of delivering a payload to a specific lung region 
(such as the deep lung).17,45,50–52 While all particles that had 
measurable sizes were within an ideal size range, the mor-
phology exhibited was not smooth and without agglomeration 
for the entire set of particles. In particular, SD particles that 
underwent the highest spray-drying rate of 30 mL/minute 
(high P systems) had the best morphology, whereas the 
low P and medium P systems were rough and agglomerated, 
which would limit the aerosolization and delivery of these 
particles via inhalation methods. Overall, the highest pump 
rate resulted in the most optimal particle set.
PXRD and DSC analysis showed that the organic solu-
tion advanced spray-drying in closed mode of dilute solu-
tions with DPPC and/or DPPE-PEG resulted in particles 
that demonstrated the presence of the lipid bilayer structure 
(multilamellar) as evidence of the signature peaks for PXRD 
and the characteristic bilayer phase-transition values of T
c
, T
p
, 
and T
m
, in DSC thermograms.24–26 PXRD data were the same 
for both the raw and SD particles and proved the presence 
of both the lipid bilayer(s) and PEG within the SD systems, 
which were not affected by a change in pump rates. A rela-
tionship was seen between the intensity of the PXRD peaks 
corresponding to PEG (at 19° and 23° 2θ) and the PEG chain 
length, where the intensity increased with increasing PEG 
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Figure 13 (A) Raman spectra obtained via confocal microscopy of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k (DPPE-PEG3k), formulated spray-dried 
(SD) dipalmitoylphosphatidylcholine (DPPC), and formulated co-SD 95 DPPC:5 DPPE-PEG3k (high P). Colored arrowheads show mapped bands. (B) Raman spectroscopic 
mapping showing the area of the Raman bands between 700 and 740 cm−1 (brighter colors indicate greater area) superimposed on a bright-field optical image of the surface 
of a particle of formulated SD DPPC (100% pump rate). (C) Map showing the area of the Raman bands between 270 and 295 cm−1. (D) Map showing the area of the Raman 
bands between 1225 and 1250 cm−1.
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Figure 14 (A) Raman spectra obtained via confocal microscopy of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-5k (DPPE-PEG5k), formulated spray-dried 
(SD) dipalmitoylphosphatidylcholine (DPPC), and formulated co-SD 95 DPPC:5 DPPE-PEG5k (high P). Colored arrowheads show mapped bands. (B) Raman spectroscopic 
mapping showing the area of the Raman bands between 700 and 740 cm−1 (brighter colors indicate greater area) superimposed on a bright-field optical image of the surface 
of a particle of formulated SD DPPC (100% pump rate). (C) Map showing the area of the Raman bands between 270 and 295 cm−1. (D) Map showing the area of the Raman 
bands between 1225 and 1250 cm−1.
chain length. DSC thermograms of pure SD DPPC particles 
showed similar T
m
 values irrespective of spray-drying pump 
rates, which corresponded to raw DPPC without a pretransi-
tion peak. This bilayer phase transition was also present in 
co-SD DPPC:DPPE-PEG particles along with a secondary 
endothermic peak, which corresponded to that of pure raw 
DPPE-PEG, neither of which was dependent on the pump 
rate. The relationship between the endothermic peak values 
exhibited by the particles and the outlet temperatures from 
the spray-drying process was likely a significant factor in 
the successful formation of multilamellar particles using the 
fastest pump rate. The outlet temperatures for the low and 
medium pump rates (3 and 15 mL/minute, respectively) were 
above the phase-transition temperatures of the formulated 
PEGylated phospholipid particles, resulting in improper 
formation and agglomeration. A higher pump rate decreased 
the outlet temperature, while allowing for the formation of 
ideally sized, smooth particles that were not agglomerated 
and properties suitable for inhalation aerosol delivery as 
dry powders.
HSM enabled visualization as a function of tempera-
ture and confirmed the phase transitions of the raw DPPC 
and DPPE-PEGs, as well as the formulated SD DPPC and 
co-SD DPPC:DPPE-PEG SD particles. It also showed the 
stability of the particles at physiological temperatures. 
ATR-FTIR analysis on the SD particles in their dry state in 
comparison to their raw components confirmed the presence 
of both DPPC and DPPE-PEG where appropriate through 
the signature peaks of each of these materials without the 
destruction of particles that would occur using other FTIR 
methods. Furthermore, organic spray-drying resulted in low 
water content of the particles, which is necessary for effective 
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Figure 15 Aerosol-dispersion performance as % deposition on each stage of the Next Generation Impactor at Q = 60 L/minute for: (A) 100 dipalmitoylphosphatidylcholine 
(DPPC) (high P), (B) 95 DPPC:5 dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) (high P), (C) 95 DPPC:5 DPPE-PEG3k (high P), and 
(D) 95 DPPC:5 DPPE-PEG5k (high P).
Note: High P correspond to 100% pump rate.
Table 4 Aerosol dispersion performance properties as aerosolized dry powders of PEGylated phospholipid particles including mass 
median aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF), 
respirable fraction (RF), and emitted dose (ED) for inhalable microparticle/nanoparticle formulations all designed and produced at high P 
(mean ± standard deviation, n = 3)
Aerosol system 100 DPPC 95 DPPC:5 DPPE-PEG2k 95 DPPC:5 DPPE-PEG3k 95 DPPC:5 DPPE-
PEG5k
MMAD (µm) 4.4 ± 0.9 4.5 ± 0.3 4.1 ± 0.2 4.0 ± 0.6
GSD (µm) 2.7 ± 0.7 2.3 ± 0.0 2.2 ± 0.3 2.1 ± 0.2
FPD (mg) 7.5 ± 1.5 9.1 ± 0.7 9.5 ± 1.1 9.0 ± 1.2
FPF (%) 23.8 ± 4.7 29.4 ± 2.8 30.2 ± 3.4 29.5 ± 4.3
RF (%) 60.3 ± 8.5 68.7 ± 5.2 71.7 ± 3.0 75.5 ± 12.8
ED (mg) 28.7 ± 1.2 29.0 ± 0.9 29.6 ± 1.2 28.6 ± 0.9
ED (%) 91.2 ± 4.0 93.1 ± 1.2 94.2 ± 2.6 93.2 ± 1.9
Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; PEG, poly(ethylene glycol).
particle delivery since residual water can have a significant 
influence on impeding the dispersion of dry powder dur-
ing aerosolization.53 These values were remarkably low for 
inhalation applications, and this is another novel advantage 
in organic solution spray-drying (ie, minimizes residual 
water content in the final powder). Raman microscopy and 
chemical imaging confirmed the chemical homogeneity of 
the particles.
Excellent aerosol dispersion performance (Figure 15) 
and optimal aerosol performance parameters (Table 4) were 
demonstrated using the NGI™ coupled with the HandiHaler® 
DPI device and clearly indicated that the formulated particles 
would be optimal for efficient and predominant deposition 
into the deep lung region for targeted delivery as inhaled 
nanoparticles/microparticles as aerosolized powders. The 
MMAD values were within the range (1–5 µm) necessary 
for particles to deposit predominantly in the middle- to deep-
lung regions and deposit by sedimentation due to gravita-
tional settling.1,7,8,52 For example, it was reported that porous 
poly(lactic-co-glycolic) microparticles exhibited MMADs 
ranging from 4.5 to 6.6 µm,5 whereas phospholipid/mannitol 
SD particles ranged from 1.25 to 1.77 µm.37 Furthermore, 
the ED, FPF, and RF values were all high compared to other 
values reported in the literature.54,55 While not all of these 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
291
Dry powder DPPC: DPPE-PEG aerosols
International Journal of Nanomedicine 2013:8
aerosol performance parameters are often reported, FPF% 
values for porous poly(lactic-co-glycolic acid) particles were 
reported to be in the range of 10.7%–33.8%5 and sodium alen-
dronate from 34.4% to 62.0%.38 The novel findings reported 
here indicate the significant potential of these lipopolymeric 
lung surfactant-mimic particles to be utilized to effectively 
deliver many different types of therapeutics to the lung as 
inhaled dry powder nanomedicine aerosols.
Conclusion
This comprehensive and systematic study demonstrated 
for the f irst time that inhalable DPPC:DPPE-PEG 
microparticles and nanoparticles with differing PEG 
lengths were rationally designed and successfully pro-
duced using the advanced organic spray-drying process 
in closed mode for dilute alcohol solutions. The SD 
lung surfactant-mimic phospholipid and lipopolymeric 
particles produced from various rationally chosen pump 
rates showed that the highest pump rate (30 mL/minute) 
resulted in particles with smooth, spherical morphology 
and optimal characteristics for inhalation aerosol delivery 
as DPIs. This was a result of the lower outlet temperatures 
exhibited, which was below the transition temperature 
of these particles. Pharmaceutical processing condi-
tions correlated in a meaningful manner with changes in 
important physicochemical and particle properties, such 
as morphology and transition temperatures, essential 
for targeted pulmonary delivery as DPIs. These novel 
particles as aerosolized dry powders of lung surfactant-
mimic and biocompatible lipopolymeric microparticles/
nanoparticles offer the potential to be used in the delivery 
of a wide variety of pulmonary drugs, owing to their 
inherent ability to encapsulate numerous types of drugs, 
controlled drug release, enhanced mucus penetration by 
phospholipid spreading and PEG penetration, and evasion 
of phagocytosis by immune cells.
Acknowledgments
The authors gratefully acknowledge financial support 
from the National Cancer Institute (NCI) grant number 
R25CA153954 and a National Cancer Institute Cancer 
Nanotechnology Training Center (NCI-CNTC)  Postdoctoral 
Traineeship awarded to SAM. The content is solely the 
responsibility of the authors and does not necessarily 
 represent the official views of the National Cancer  Institute 
or the National Institutes of Health. The authors thank 
Dr Tonglei Li for PXRD and HSM access, and Dr J Zach 
Hilt for ATR-FTIR access.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Carvalho TC, Carbalho SR, McConville JT. Formulations for pulmonary 
administration of anticancer agents to treat lung malignancies. J Aerosol 
Med Pulm Drug Deliv. 2011;24:61–80.
 2. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. 
Int J Nanomedicine. 2009;4:299–319.
 3. Vaughn JM, McConville JT, Burgess D, et al. Sing dose and multiple 
dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm. 
2006;63:95–102.
 4. Gill S, Löbenberg R, Ku T, Azarmi S, Roa WH, Prenner EJ.  Nanoparticles: 
characteristics, mechanisms of action, and toxicity in pulmonary drug 
delivery – a review. J Biomed Nanotechnol. 2007;3:107–119.
 5. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of 
highly porous large PLGA microparticles for pulmonary drug delivery. 
Biomaterials. 2009;30:1947–1953.
 6. Sharma S, White D, Imondi A, Placke ME, Vail DM, Kris MG. 
Development of inhalation agents for oncologic use. J Clin Oncol. 
2001;19:1839–1847.
 7. Hickey AJ, Mansour HM. Delivery of drugs by the pulmonary route. 
In: Florence AT, Siepmann J, editors. Modern Pharmaceutics. 5th ed. 
New York: Taylor and Francis; 2009;2:191–219.
 8. Hickey AJ, Mansour HM. Formulation challenges of powders 
for the delivery of small molecular weight molecules as aerosols. 
In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, editors. 
 Modified-Release Drug Delivery Technology. 2nd ed. New York: 
Informa Healthcare; 2008;2:573–602.
 9. Arnold MM, Gonnan EM, Schieber LJ, Munson EJ, Berkland C. 
NanoCipro encapsulation in monodisperse large porous PLGA 
 microparticles. J Control Release. 2007;121:100–109.
 10. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, 
Saltzman WM. Partial correction of cystic fibrosis defects with 
PLGA nanoparticles encapsulating curcumin. Mol Pharm. 2010;7: 
86–93.
 11. Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, 
Ainslie KM. Synthesis, optimization, and  characterization of 
 camptothecin-loaded acetalated dextran porous microparticles for 
pulmonary delivery. Mol Pharm. 2012;9:290–298.
 12. Oh YJ, Lee J, Seo JY, et al. Preparation of budesonide-loaded porous 
PLGA microparticles and their therapeutic efficacy in a murine asthma 
model. J Control Release. 2011;150:56–62.
 13. Wu XA, Li XJ, Mansour HM. Surface analytical techniques in solid-
state particle characterization for predicting performance in dry powder 
inhalers. Kona Powder Part J. 2010;28:3–19.
 14. Mansour HM, Rhee YS, Park CW, DeLuca PP. Lipid nanoparticulate 
drug delivery and nanomedicine. In: Moghis A, editor. Lipids in Nano-
technology. Urbana (IL): American Oil Chemists Society (AOCS) Press; 
2011:221–268.
 15. Watts AB, McConville JT, Williams RO. Advancements in dry powder 
delivery to the lung. Drug Dev Ind Pharm. 2008;34:948–959.
 16. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body 
through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
 17. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to 
the lungs. Trends Biotechnol. 2007;25:563–570.
 18. Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary 
specialist should know about inhalation therapies. Eur Respir J. 
2011;37:1308–1331.
 19. Xu Z, Mansour HM, Hickey AJ. Particle interations in dry powder 
inhaler unit processes. J Adhes Sci Technol. 2011;25:451–482.
 20. Rhee YS, Mansour HM. Nanopharmaceuticals I: nanocarrier systems in 
drug delivery. Invited paper. Int J Nanotechnology. 2011;8:84–114.
 21. Wu X, Mansour HM. Nanopharmaceuticals II: application of nano-
particles and nanocarrier systems in pharmaceutics and nanomedicine. 
Invited paper. Int J Nanotechnology. 2011;8:115–145.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
292
Meenach et al
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2013:8
 22. Willis L, Hayes DJ, Mansour HM. Therapeutic liposomal dry powder inha-
lation aerosols for targeted lung delivery. Lung. 2012;190:251–262.
 23. Ganguly S, Moolchandani V, Roche JA, et al. Phospholipid-induced 
in vivo particle migration to enhance pulmonary deposition. J Aerosol 
Med Pulm Drug Deliv. 2008;23:181–187.
 24. Mansour HM, Zografi G. The relationship between water vapor absorp-
tion and desorption by phospholipids and bilayer phase transitions. 
J Pharm Sci. 2007;96:377–396.
 25. Mansour H, Wang DS, Chen CS, Zografi G. Comparison of bilayer 
and monolayer properties of phospholipid systems containing 
dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol. 
 Langmuir. 2001;17:6622–6632.
 26. Mansour HM, Zografi G. Relationships between equilibrium spreading 
pressure and phase equilibria of phospholipid bilayers and monolayers 
at the air-water interface. Langmuir. 2007;23:3809–3819.
 27. Mansour HM, Damodaran S, Zografi G. Characterization of the in situ 
structural and interfacial properties of the cationic hydrophobic het-
eropolypeptide, KL
4
, in lung surfactant bilayer and monolayer models at 
the air-water interface: implications for pulmonary surfactant delivery. 
Mol Pharm. 2008;5:681–695.
28. Mabrey S, Sturtevant JM. Investigation of phase transitions of lipids 
and lipid mixtures by high sensitivity differential scanning calorimetry. 
Proc Natl Acad Sci U S A. 1976;73:3862–3866.
 29. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiologi-
cal factors affecting therapeutic effectiveness of aerosolized medica-
tions. Br J Clin Pharmacol. 2003;56:588–599.
 30. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the 
role of inhalant delivery devices and drug formulation in therapeu-
tic effectiveness of aerosolized medications. Br J Clin Pharmacol. 
2003;56:600–612.
 31. Ishihara K, Nomura H, Mihara T, Kurita K, Iwasaki Y, Nakabayashi N. 
Why do phospholipid polymers reduce protein adsorption? J Biomed 
Mater Res. 1998;39:323–330.
 32. Mansour HM, Sohn M, Al-Ghananeem A, Deluca PP. Materials for 
pharmaceutical dosage forms: molecular pharmaceutics and controlled 
release drug delivery aspects. Int J Mol Sci. 2010;11:3298–3322.
 33. Lai SK, O’Hanlon DE, Harrold S, et al. Rapid transport of large poly-
meric nanoparticles in fresh undiluted human mucus. Proc Natl Acad 
Sci U S A. 2007;104:1482–1487.
 34. Sadikot RT, Rubinstein I. Long-acting, multi-targeted  nanomedicine: 
addressing unmet medical need in acute lung injury. J Biomed 
 Nanotechnol. 2009;5:614–619.
 35. Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Önyüksel H. A novel 
peptide nanomedicine against acute lung injury: GLP-1 in phospholipid 
micelles. Pharm Res. 2011;28:662–672.
 36. Kikuchi H, Yamauchi H, Hirota S. A spray-drying method for mass 
production of liposomes. Chem Pharm Bull. 1991;36:1522–1527.
 37. Alves GP, Santana MHA. Phospholipid dry powders produced by spray 
drying processing: structural, thermodynamic and physical properties. 
Powder Technol. 2004;145:139–148.
 38. Cruz L, Fattal E, Tasso L, et al. Formulation and in vivo evaluation 
of sodium alendronate spray-dried microparticles intended for lung 
delivery. J Control Release. 2011;152:370–375.
 39. Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation 
excipients and physical characterisitcs of inhalation dry powders on their 
aerosolization performance. J Control Release. 2001;70:329–339.
 40. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inha-
lation of insulin-loaded liposomes for enhanced pulmonary delivery. 
J Drug Target. 2008;16:639–648.
 41. Masters K. Spray Drying Handbook. 5th ed. Harlow, UK: Longman; 
1991.
 42. Li X, Mansour HM. Physicochemical characterization and water vapor 
absorption of organic solution advanced spray dried trehalose micropar-
ticles and nanoparticles for targeted dry powder pulmonary inhalation 
delivery. AAPS Pharm Sci Tech. 2011;12:1420–1430.
 43. Park CW, Rhee YS, Vogt F, et al. Advances in microscopy and comple-
mentary imaging techniques to assess the fate of drugs ex-vivo in 
respiratory drug delivery: an invited paper. Adv Drug Deliv Rev. 
2012;64:344–356.
 44. Chapter 601. Aerosols, nasal sprays, metered-dose inhalers, and dry 
powder inhalers monograph. In: USP 29-NF 24: United States Phar-
macopoeia and the National Formulary: The Official Compendia of 
Standards. Vol 29/24. Rockville, MD: United States Pharmacopeial 
Convention; 2006:2617–2636.
 45. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary 
drug delivery using large, porous inhaled particles. J Appl Physiol. 
1998;85:379–385.
 46. Kang E, Robinson J, Park K, Cheng JX. Paclitaxel distribution in 
poly(ethylene glycol)/poly(lactide-co-glycolic acid) blends and its 
release visualized by coherent anti-Stokes Raman scattering  microscopy. 
J Control Release. 2007;122:261–268.
 47. Jones BG, Dickinson PA, Gumbleton M, Kellaway IW. The inhibition 
of phagocytosis of respirable microspheres by alveolar and peritoneal 
macrophages. Int J Pharm. 2002;236:65–79.
 48. Wu YP, Zuo F, Zheng ZH, Ding XB, Peng YX. A novel approach to 
molecular recognition surface of magnetic nanoparticles based on 
host-guest effect. Nanoscale Res Lett. 2009;4:738–747.
 49. Li X, Hayes D, Mansour HM. Targeted lung delivery by inhalable 
multifunctional microparticulate/nanoparticulate aerosols for cystic 
fibrosis combination drug/mucolytic treatment. Pediatric Pulmonology. 
2011:34 Suppl:346.
 50. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles 
for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60: 
863–875.
 51. Gautam A. Targeted delivery of therapeutics by aerosol for cancer of 
the lung. Curr Cancer Drug Targets. 2003;3:57.
 52. Edwards DA. The macrotransport of aerosol particles in the lung: aerosol 
deposition phenomena. J Aerosol Sci. 1995;26:293–317.
 53. Hickey AJ, Mansour HM, Telko MT, et al. Physical characterization of 
component particles included in dry powder inhalers. I. Strategy review 
and static characteristics. J Pharm Sci. 2007;96:1282–1301.
 54. Vanbever R, Ben-Jebria A, Mintzes J, Langer C, Edwards DA.  Sustained 
release of insulin from insoluble inhaled particles. Drug Dev Res. 
1999;48:178–185.
 55. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI.  Cyclodextrins 
in the production of large porous particles: development of dry  powders 
for the sustained release of insulin to the lungs. Eur J Pharm Sci. 
2006;28:423–432.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
293
Dry powder DPPC: DPPE-PEG aerosols
